Cardiogen

Most Common Uses

Cardiogen is primarily explored for its cardiovascular benefits, particularly in conditions involving impaired heart function or restricted blood flow. Its most common applications stem from its angiogenic properties, which encourage the formation of new blood vessels, and its cardioprotective effects, which help shield heart tissue from damage.

Cardiovascular Support

Cardiogen is frequently studied for its potential to improve heart function in cases of myocardial infarction (heart attack) and ischemic heart disease. By stimulating angiogenesis, it enhances blood supply to oxygen-deprived tissues, aiding in the recovery of damaged myocardium. Researchers also investigate its role in managing heart failure, where it may support cardiac remodeling and improve pump efficiency.

Cellular Regeneration Across Tissues

Beyond the heart, Cardiogen shows promise in supporting regeneration in various tissues, including the liver, kidneys, and nervous system. Studies indicate it may influence stem cell activity, guiding differentiation into specialized cell types needed for tissue repair.

Metabolic Regulation

Cardiogen’s potential to regulate energy metabolism at the cellular level is another key area of interest. It may impact metabolic processes in muscle and adipose tissues, which are often disrupted in cardiovascular diseases and diabetes. Cardiogen could contribute to research strategies aimed at mitigating chronic metabolic disorders due to these effects.

Cellular Aging

The peptide’s role in counteracting cellular aging is under investigation, particularly in tissues prone to wear, such as the cardiovascular and muscular systems. Cardiogen may enhance regenerative capacity and slow the decline of tissue function, making it relevant to studies on age-related degeneration and longevity.

Warnings and Cautions

As an experimental peptide, Cardiogen lacks comprehensive safety data for human use. Its effects are primarily studied in animal models and cell cultures, and clinical application is not yet established. Potential risks include unintended cellular proliferation or interactions with other biological pathways, particularly given its observed effects on tumor cells in preclinical studies.

While specific side effects remain understudied, peptide administration may cause localized reactions such as injection-site irritation or, in rare cases, systemic effects like immune responses.

Cardiogen is contraindicated in individuals with known peptide sensitivities or active cancers, as its angiogenic properties could theoretically promote tumor growth. However, this hypothesis needs further investigation to understand its specificity and long-term safety.

Dosages

No standardized dosages for Cardiogen exist for human use, as it remains in the preclinical research phase. However, typical dosages used in research and clinical settings are around 1-5 mg per day, administered either orally or via injection.

Mechanism of Action

Cardiogen is thought to exert its effects by modulating cellular signaling pathways in cardiac and tumor cells. In cardiac tissue, it appears to stimulate fibroblast proliferation while suppressing apoptosis in cardiomyocytes, potentially by downregulating p53 protein expression, a key regulator of cell death. This dual action may reduce scar formation and enhance tissue repair in models of cardiac remodeling.

In tumor cells, Cardiogen induces apoptosis and hemorrhagic necrosis, likely by disrupting the tumor’s vascular network rather than directly acting as a cytostatic agent. It may penetrate cells, localizing in the cytoplasm, nucleus, and nucleolus, and inhibit endonuclease-catalyzed DNA hydrolysis, further influencing cellular metabolism. These mechanisms are hypothesized based on preclinical data and require confirmation in more robust studies.

Structure and Pharmacology

Cardiogen is a tetrapeptide with the sequence H-Ala-Glu-Asp-Arg-OH, consisting of alanine, glutamic acid, aspartic acid, and arginine. Its small size and polar amino acid composition allow it to penetrate cell membranes, reaching intracellular compartments like the nucleus and nucleolus. The peptide’s structure is synthesized using solid-phase peptide synthesis.

Cardiogen’s pharmacokinetic profile is poorly characterized due to its experimental status. In vitro studies suggest it upregulates cytoskeletal proteins (actin, vimentin, tubulin) and nuclear matrix proteins (lamin A, lamin C) in fibroblasts, potentially enhancing cell proliferation and differentiation. Its ability to modulate p53 expression indicates a role in apoptosis regulation, though the exact binding targets and signaling pathways remain unclear. The peptide’s short half-life and potential susceptibility to proteolytic degradation are challenges for therapeutic development, necessitating further research into delivery systems or structural modifications.

History

Cardiogen was developed as part of research into short-chain peptides with bioregulatory potential, pioneered by Russian scientists in the late 20th century. It emerged from studies at institutions like the St. Petersburg Institute of Bioregulation and Gerontology, where researchers explored peptides for their ability to modulate cellular functions in aging and disease. Initially investigated for its cardiovascular effects, Cardiogen gained attention in the early 2000s for its ability to influence fibroblast activity and cardiomyocyte survival in preclinical models.

Concurrently, its tumor-modifying properties were observed in oncology research, particularly in rat sarcoma models, broadening its investigative scope. Despite decades of study, Cardiogen remains an experimental compound, with no transition to clinical trials as of 2025, reflecting challenges in translating peptide-based therapies to human applications.

Research on Cardiogen

Effects on Heart Tissue

One study explored how 20 different amino acids and a synthetic compound called cardiogen affect heart tissue growth in lab cultures, using tissue from young rats (3 months old) and older rats (24 months old). The researchers found that seven of the amino acids boosted cell growth in the heart tissue from young rats, but only two had a similar effect in the tissue from older rats, showing that older tissue is less responsive.

However, cardiogen stood out, as it strongly encouraged cell growth in heart tissue from both young and old rats. Additionally, when the researchers looked at the tissue under a microscope, they noticed that cardiogen lowered levels of a protein called p53, which suggests it helps prevent the cells from undergoing programmed cell death, or apoptosis. [1]

Effects On the Prostate Gland

Another study looked at how three short peptides, named T-32, T-38, and cardiogen, influence the behavior of fibroblast cells in the human prostate gland as those cells age in lab cultures. Fibroblasts are key cells in the prostate’s environment, and the researchers focused on how these peptides affect the production of three specific signaling proteins, CXCL12, WEDC1, and ghrelin, which are important for cell differentiation and function.

Using a technique called confocal laser microscopy, they found that all three peptides significantly boosted the production of these proteins in aging fibroblast cultures, where their levels naturally drop. Interestingly, in older cell cultures (after seven rounds of cell division), the peptides not only restored protein production but sometimes pushed it even higher than in younger cultures (after just one round of division). [2]

Effects of Cardiogen on Tumore Cells

Research investigated the effects of a peptide called cardiogen on M-1 sarcoma, a type of tumor, in older rats. The researchers found that when cardiogen was injected, it increased the rate of apoptosis (programmed cell death) in tumor cells across all experimental groups compared to the control group, which received no treatment. The peptide also slowed the growth of the sarcoma in a dose-dependent manner, meaning higher doses led to greater tumor suppression.

This tumor shrinkage was linked to two main effects: the development of hemorrhagic necrosis (tissue death due to disrupted blood supply) and the boosting of apoptosis in tumor cells. However, the study noted that cardiogen didn’t directly act as a cytostatic agent, meaning it didn’t stop tumor growth by halting cell division. Instead, its effects seemed to work through a specific mechanism involving the tumor’s blood vessel network, as suggested by the observed morphological changes. [3]